SCHEMBL1888198

SCHEMBL1888198

Cc1ccc2cc(CO)c(-c3ccccc3)nc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.57
ALDH1A1 P00352 6/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
TDP1 Q9NUW8 1/20 0.47
KMT2A Q03164 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PDE10A Q9Y233 2/20 0.45
HPGD P15428 3/20 0.45
RAB9A P51151 3/20 0.45
HSD17B10 Q99714 2/20 0.45
MAPK1 P28482 1/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
DHODH Q02127 1/20 0.44
LMNA P02545 2/20 0.43
MAPT P10636 1/20 0.43
NPC1 O15118 2/20 0.43
MEN1 O00255 1/20 0.43
PSMB5 P28074 1/20 0.42
NLRP3 Q96P20 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1884067 0.88 KDM4E (0.57) KDM4EALDH1A1L3MBTL1TDP1KMT2A
SCHEMBL1884703 0.85 KDM4E (0.57) KDM4EALDH1A1L3MBTL1TDP1KMT2A
SCHEMBL1888175 0.82 KMT2A (0.43) KDM4EALDH1A1L3MBTL1KMT2ANPSR1
SCHEMBL1882100 0.82 PDE10A (0.56) KDM4EALDH1A1L3MBTL1TDP1KMT2A
SCHEMBL28528610 0.79 PDE10A (0.71) KDM4EALDH1A1L3MBTL1TDP1KMT2A
SCHEMBL3386971 0.77 KDM4E (0.54) KDM4EALDH1A1L3MBTL1TDP1KMT2A
SCHEMBL17942814 0.76 ALDH1A1 (0.62) KDM4EALDH1A1L3MBTL1TDP1KMT2A
SCHEMBL27961602 0.76 KDM4E (0.62) KDM4EALDH1A1L3MBTL1TDP1KMT2A
Ammonia Solution, Strong SCHEMBL27721764 0.75 KDM4E (0.41) KDM4EALDH1A1KMT2ANPSR1HPGD
SCHEMBL8644046 0.74 KMT2A (0.73) KDM4EALDH1A1L3MBTL1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed
EP-2231641-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2010-09-29 EP disclosed
WO-2009081105-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE KDM4E 2230/4885ALDH1A1 4276/4885L3MBTL1 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.